抗纤维化中成药联合熊去氧胆酸治疗原发性胆汁性胆管炎的系统评价与Meta分析
本研究通过检索多个数据库至2022年8月的随机对照试验,评估抗纤维化中成药联合熊去氧胆酸治疗原发性胆汁性胆管炎的疗效与安全性。共纳入22项RCT、1725例患者,Meta分析显示联合治疗在提高有效率、改善肝功能、肝纤维化、免疫指标及临床症状方面均优于单用熊去氧胆酸(均p<0.05)。结论认为联合治疗可改善临床症状和结局,但仍需更多高质量RCT验证。
要点
- 抗纤维化中成药联合UDCA可提高PBC患者临床有效率。
- 联合治疗在改善肝功能、肝纤维化及免疫指标方面优于单用UDCA。
- 联合治疗可改善临床症状,但证据质量受限于原始研究。
核心结论
- 抗纤维化中成药联合熊去氧胆酸可改善原发性胆汁性胆管炎患者的临床症状和结局。
- 仍需更多高质量随机对照试验评估抗纤维化中成药治疗PBC的有效性。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Web of Science、Embase、Cochrane Library、万方、维普、中国生物医学文献数据库及中国知网,检索时间从建库至2022年8月。
- 纳入抗纤维化中成药治疗原发性胆汁性胆管炎的随机对照试验,采用Cochrane偏倚风险工具评估文献质量。
- 共纳入22项随机对照试验,涉及1725例患者。
主要发现
- 与单用熊去氧胆酸相比,抗纤维化中成药联合熊去氧胆酸可提高临床有效率(p<0.05)。
- 联合治疗可改善肝功能、肝纤维化、免疫指标及临床症状(均p<0.05)。
- 二分类变量采用风险比(RR)评估,连续变量采用均数差及95%置信区间计算。
关键数值与推荐
- 纳入22项RCT、1725例患者,联合治疗在有效率、肝功能、肝纤维化、免疫指标及症状评分方面均优于单用UDCA(均p<0.05)。
临床怎么用
- 对于原发性胆汁性胆管炎患者,可考虑在熊去氧胆酸基础上联合抗纤维化中成药以改善疗效。
- 临床决策需结合患者具体情况,并注意现有证据质量有限。
局限性
- 需要更多高质量随机对照试验来评估抗纤维化中成药治疗PBC的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To delineate the curative effect and safety of anti-fibrosis Chinese patent medicines (CPMs) combined with ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC). Methods: A literature search was conducted using PubMed, Web of Science, Embase, Cochrane Library, Wanfang database, VIP database, China Biology Medicine Database, and Chinese National Knowledge Infrastructure from their inception until August 2022. Randomized controlled trials (RCTs) of the treatment of PBC with anti-fibrotic CPMs were collected. The eligibility of the publications was assessed using the Cochrane risk-of-bias tool. The evaluation indicators were the clinical efficacy rate, liver fibrosis, liver function, immune function, and symptom score. Meta-analysis and subgroup analysis were conducted to evaluate the effectiveness of anti-fibrosis CPMs. Risk ratio (RR) was used to assess dichotomous variables, and continuous variables with a 95% confidence interval were calculated using mean difference. Results: Twenty-two RCTs including 1,725 patients were selected. The findings demonstrated that anti-fibrotic CPMs combined with UDCA improved the efficacy rate, liver function, liver fibrosis, immunological indicators, and clinical symptoms compared with UDCA alone (all p < 0.05). Conclusion: This study demonstrates that the combination of anti-fibrotic CPMs and UDCA can improve both clinical symptoms and outcomes. Nevertheless, more high-quality RCTs are needed to assess the effectiveness of anti-fibrosis CPMs for PBC.
引用
- Bi Y, Shi K, Chen J, et al. Curative effect of anti-fibrosis Chinese patent medicines combined with ursodeoxycholic acid for primary biliary cholangitis: A systematic review and meta-analysis. Front Pharmacol. 2023. PMID: 37025490. doi:10.3389/fphar.2023.1159222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。